BOARD OF DIRECTORS
Ron Eastman, Chairman
Mr. Eastman has over 28 years of experience in building healthcare businesses. He began his career at American Cyanamid Company which was acquired by American Home Products (now Wyeth). At Cyanamid, Mr. Eastman spent 15 years managing various pharmaceutical products, divisions and subsidiaries in the US and overseas. Since then, he has helped build three private healthcare companies. Under his leadership, Geron became a cutting edge biotech company that grew from a venture-backed startup to a publicly traded pioneer in the fields of regenerative medicine and cancer. HCORP quickly established itself as the technology and market leader in the emerging field of hospital-based, interactive patient services and was sold to a diversified competitor. Most recently, Rinat Neuroscience, a private biotech company spun out of Genentech in late 2001, Mr. Eastman led the effort to recruit an experienced management team, raise over $65 Million in venture and corporate capital, and move Rinat's first product for the treatment of pain into clinical trials.
Mr. Eastman has served on the Board of BIO, the biotechnology trade organization, and currently serves as a trustee at The Buck Institute, the largest non-profit research institute in the US studying diseases of aging. Mr. Eastman earned his BA from Williams College and his MBA from Columbia.
Mr. Evans, General Partner, is a veteran venture capitalist with more than three decades of investment experience. He focuses on consumer retail, financial services, technology and special situation investments. Since joining INVESCO Private Capital in 1995, Mr. Evans has led investments in Accessline, Ambit Design Systems, AnyTime Access, Broadquest, Callidus, Comergent, CommQuest, Digital Insight,, Docent, E2open, General Bandwidth, HMT Technology Corporation, InfiCorp Holdings, StarVox, Skywire, ClearCross, 2Wire, Wayport and Wherenet. Mr. Evans serves on the board of several private companies.
In 1990, Mr. Evans joined Wolfensohn Partners as a General Partner. Wolfensohn Partners is the General Partner of Wolfensohn Associates, a $70 Million venture capital fund. Prior to Wolfensohn Partners, he established Kuwait Middle East Financial Investment Co., a joint venture between BKME and the Kuwait Public Institute for Social Security. In 1987, Mr. Evans established KME Management Services, Inc., as President, where he was responsible for venture capital and real estate investments of partnership funds raised in Kuwait. From 1980, Mr. Evans was the General Manager of Bank of Kuwait and the Middle East. Mr. Evans began his career in 1970 at Morgan Guaranty and rose to the position of Vice President, working in the general banking, treasury, foreign exchange, budgeting and planning areas both in New York and Belgium. Mr. Evans received a BA in Political Science from Boston University in 1970.
Elizabeth Posillico, PhD
Dr. Posillico has 20 years of experience in the biopharmaceutical industry and has held senior positions in general management, business development, marketing and operations. She joined Elusys in 2002 as Vice President of Business Development and since then was promoted to Sr. Vice President of Operations and then President and CEO in January 2005. Prior to joining Elusys, she was Vice President of Business Development and Marketing at Physiome Sciences, Sr. Vice President of Business Development at Apoptogen, Inc., a Canadian biotech company developing novel therapies for the treatment of apoptosis-related diseases. She also also served on the management committee of the Canadian Medical Discovery Fund, an early-stage venture capital fund. Dr. Posillico spent eight years at Genzyme Corporation in several positions including Director of Sales and Marketing for ImmunoBiological Products and ultimately as General Manager and Sr. Vice President in the Diagnostics Division.
She currently serves on the New Jersey Governor’s Economic Growth Council and is a member of the Board of Directors of BioNJ, the Biotechnology Council of New Jersey, and the Girl Scouts of Northern New Jersey. Dr. Posillico received a BA degree from the State University of New York at Potsdam and a PhD from Duke University.
Mr. Wolf has substantial experience in creating, financing, nurturing and growing new ventures based upon breakthrough research and technology. Mr. Wolf is the founding partner of Seed-One Ventures, LLC, a venture capital group focused on seed-stage technology-based investments. Mr. Wolf was founder of Elusys Therapeutics, Tyrx Pharma, Inc., a company focused on the development of robust resorbable polymer systems, Avigen, a gene therapy company and GenerationOne, Inc. a mobile-based disease management company. Prior to founding Seed-One Ventures, Mr. Wolf served as the Managing Director of The Castle Group, Ltd., a biomedical venture capital firm. At both organizations, Mr. Wolf was responsible for supervising the formation and funding of new life science ventures. Mr. Wolf received his MBA from Stanford Business School, his JD from New York University School of Law and his BA with honors in Economics from the University of Chicago.
Frank Young, MD, PhD
Dr. Young has an extensive background in microbiology, immunology, regulatory and defense-related affairs. Dr. Young has published over 200 papers in the field of biotechnology. Dr. Young was formerly Commissioner of the FDA. Dr. Young's other public service work includes positions as a Rear Admiral in the US Public Health Service, Deputy Assistant Secretary for Health, and a senior advisor to DARPA. Dr. Young is also a member of the Institute of Medicine of the National Academy of Sciences. Dr. Young received his MD from the University of the State of New York and his PhD from Western Reserve University.